ICU Medical (NASDAQ:ICUI) Upgraded at Wall Street Zen

Key Points

• Wall Street Zen upgraded ICU Medical from hold to buy, while Jefferies also raised its view to strong-buy. Overall, analysts now rate the stock a consensus buy with a $169 price target.
• ICU Medical beat first-quarter expectations, posting EPS of $1.97 versus the $1.78 estimate and revenue of $525.77 million versus $520.65 million expected. The company also issued FY2026 EPS guidance of $7.75 to $8.45.
• Despite the earnings beat, revenue fell 12.3% year over year, highlighting continued pressure on top-line growth. The stock opened at $126.43, well below its 12-month high of $160.29.

ICU Medical (NASDAQ:ICUI - Get Free Report) was upgraded by investment analysts at Wall Street Zen from a "hold" rating to a "buy" rating in a report released on Saturday.

ICUI has been the topic of a number of other research reports. Jefferies Financial Group raised shares of ICU Medical to a "strong-buy" rating in a research report on Thursday. KeyCorp cut their price objective on shares of ICU Medical from $180.00 to $164.00 and set an "overweight" rating on the stock in a research report on Monday, April 27th. Piper Sandler cut their price objective on shares of ICU Medical from $178.00 to $163.00 and set an "overweight" rating on the stock in a research report on Friday, April 17th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of ICU Medical in a research report on Thursday, January 22nd. Two equities research analysts have rated the stock with a Strong Buy rating, two have given a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, ICU Medical presently has an average rating of "Buy" and a consensus price target of $169.00.

ICU Medical Stock Performance

Shares of ICUI stock opened at $126.43 on Friday. The company's fifty day simple moving average is $128.93 and its 200-day simple moving average is $138.35. The company has a quick ratio of 1.15, a current ratio of 2.39 and a debt-to-equity ratio of 0.60. The firm has a market cap of $3.16 billion, a PE ratio of 68.34, a P/E/G ratio of 1.77 and a beta of 0.74. ICU Medical has a 12 month low of $107.00 and a 12 month high of $160.29.

ICU Medical (NASDAQ:ICUI - Get Free Report) last announced its quarterly earnings data on Thursday, May 7th. The medical instruments supplier reported $1.97 EPS for the quarter, topping analysts' consensus estimates of $1.78 by $0.19. The business had revenue of $525.77 million for the quarter, compared to analyst estimates of $520.65 million. ICU Medical had a net margin of 2.15% and a return on equity of 7.49%. The firm's revenue for the quarter was down 12.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.72 earnings per share. ICU Medical has set its FY 2026 guidance at 7.750-8.450 EPS. Equities research analysts expect that ICU Medical will post 6.31 EPS for the current fiscal year.

Hedge Funds Weigh In On ICU Medical

A number of institutional investors have recently added to or reduced their stakes in the company. Maryland State Retirement & Pension System increased its holdings in ICU Medical by 2.0% during the fourth quarter. Maryland State Retirement & Pension System now owns 3,619 shares of the medical instruments supplier's stock worth $516,000 after buying an additional 70 shares during the last quarter. California Public Employees Retirement System increased its holdings in ICU Medical by 0.3% during the first quarter. California Public Employees Retirement System now owns 30,461 shares of the medical instruments supplier's stock worth $3,934,000 after buying an additional 90 shares during the last quarter. Arizona State Retirement System increased its holdings in ICU Medical by 1.3% during the third quarter. Arizona State Retirement System now owns 6,903 shares of the medical instruments supplier's stock worth $828,000 after buying an additional 91 shares during the last quarter. Oregon Public Employees Retirement Fund increased its holdings in ICU Medical by 1.8% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 5,631 shares of the medical instruments supplier's stock worth $803,000 after buying an additional 100 shares during the last quarter. Finally, Smartleaf Asset Management LLC increased its holdings in ICU Medical by 11.6% during the second quarter. Smartleaf Asset Management LLC now owns 969 shares of the medical instruments supplier's stock worth $128,000 after buying an additional 101 shares during the last quarter. 96.10% of the stock is currently owned by institutional investors and hedge funds.

More ICU Medical News

Here are the key news stories impacting ICU Medical this week:

• Positive Sentiment: ICU Medical beat Q1 expectations on both earnings and revenue, reporting EPS of $1.97 versus the $1.78 consensus and revenue of $525.77 million versus $520.65 million expected. Article Title
• Positive Sentiment: The company also issued FY2026 EPS guidance of $7.75 to $8.45, slightly above the market’s expectation, which supports the view that profitability could improve further this year. Article Title
• Positive Sentiment: Jefferies upgraded ICU Medical to strong-buy, adding to investor optimism around the stock. Article Title
• Neutral Sentiment: Transcript and post-earnings coverage indicate that strength in infusion systems and consumables helped offset weakness in the Vital Care segment, suggesting mixed underlying trends within the business. Article Title
• Neutral Sentiment: Options activity showed surging implied volatility, signaling that traders expect a larger-than-usual move in the stock after earnings. Article Title
• Negative Sentiment: Revenue still fell 12.3% year over year, showing that ICU Medical is beating estimates but still facing pressure on top-line growth. Article Title

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.